德孚在中国

9 7 3 1 6

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

卵巢靶向治疗清除细胞癌

 

Authors Jin Y, Li Y, Pan LY

Published Date September 2014 Volume 2014:7 Pages 1647—1652

DOI http://dx.doi.org/10.2147/OTT.S49993

Received 1 July 2014, Accepted 24 July 2014, Published 23 September 2014

Approved for publication by Professor Jianmin Xu

Abstract: Clear cell adenocarcinoma (CCC) of the ovary accounts for 10% of epithelial ovarian cancer and is a distinct entity from other epithelial ovarian carcinomas. It arises from the endometriosis. CCC has specific biological and clinical behavior. Compared with other histological types, CCC shows a chemoresistant phenotype, which leads to poorer prognosis. Thus, development of new target-based therapies remains an unmet need for these patients. Mutations in the gene ARID1A  have been found to occur in high frequency in CCC. The majority of these mutations lead to a loss of expression of the ARID1A protein, which is a subunit of the SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex and considered as a bona fide tumor suppressor. Upregulation of the PIK3/AKT/mTOR pathway, particularly through mutations of PIK3CA  and inactivation of PTEN , is involved in tumorigenesis of CCC. Targeting angiogenesis, the Met protooncogene pathway, and HER2  are also discussed in this review.
Keywords: ARID1A, PIK3/AKT/mTOR pathway, angiogenesis, Met protooncogene pathway, HER2




Download Article[PDF]